ASKA Pharmaceutical Holdings Co.,Ltd. (TYO:4886)
Japan · Delayed Price · Currency is JPY 2,134.00
+3.00 (0.14%)
Aug 4, 2026, 12:33 PM JST
TYO:4886 Ratios and Metrics
Market cap in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 60,512 | 67,015 | 65,350 | 62,863 | 33,620 | 35,672 | |
Market Cap Growth | -13.38% | 2.55% | 3.96% | 86.98% | -5.75% | -14.52% |
Enterprise Value | 67,386 | 80,153 | 62,609 | 52,614 | 28,088 | 28,719 |
Last Close Price | 2131.00 | 2360.00 | 2246.01 | 2111.52 | 1108.60 | 1161.34 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 11.15 | 12.36 | 12.81 | 8.33 | 7.93 | 8.32 |
Forward PE | 12.96 | 12.16 | 12.36 | 12.20 | 7.39 | 9.51 |
PS Ratio | 0.85 | 0.94 | 1.02 | 1.00 | 0.56 | 0.63 |
PB Ratio | 0.79 | 0.87 | 0.94 | 1.01 | 0.62 | 0.73 |
P/TBV Ratio | 0.98 | 1.09 | 1.12 | 1.07 | 0.67 | 0.84 |
P/FCF Ratio | 16.12 | 17.85 | - | 378.69 | 11.63 | 15.76 |
P/OCF Ratio | 9.60 | 10.63 | 26.30 | 42.30 | 10.03 | 12.55 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 0.95 | 1.13 | 0.98 | 0.84 | 0.47 | 0.51 |
EV/EBITDA Ratio | 7.81 | 8.99 | 8.26 | 5.74 | 3.41 | 3.74 |
EV/EBIT Ratio | 12.16 | 13.74 | 11.74 | 8.09 | 5.50 | 5.99 |
EV/FCF Ratio | 17.95 | 21.35 | - | 316.95 | 9.72 | 12.69 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.15 | 0.15 | 0.16 | 0.15 | 0.23 | 0.29 |
Debt / EBITDA Ratio | 1.28 | 1.28 | 1.44 | 1.04 | 1.53 | 1.83 |
Debt / FCF Ratio | 3.05 | 3.05 | - | 57.14 | 4.37 | 6.21 |
Net Debt / Equity Ratio | 0.01 | 0.01 | 0.00 | -0.12 | -0.10 | -0.06 |
Net Debt / EBITDA Ratio | 0.05 | 0.05 | -0.03 | -0.85 | -0.64 | -0.40 |
Net Debt / FCF Ratio | 0.11 | 0.11 | 0.54 | -46.70 | -1.83 | -1.35 |
Asset Turnover | 0.67 | 0.67 | 0.67 | 0.71 | 0.71 | 0.68 |
Inventory Turnover | 1.33 | 1.33 | 1.40 | 1.69 | 1.95 | 2.06 |
Quick Ratio | 1.21 | 1.21 | 1.15 | 1.37 | 1.88 | 1.97 |
Current Ratio | 2.76 | 2.76 | 2.54 | 2.34 | 3.05 | 3.10 |
Return on Equity (ROE) | 7.70% | 7.70% | 7.78% | 12.96% | 8.20% | 9.19% |
Return on Assets (ROA) | 3.43% | 3.43% | 3.48% | 4.57% | 3.75% | 3.61% |
Return on Invested Capital (ROIC) | 5.90% | 6.42% | 7.14% | 9.62% | 8.50% | 6.94% |
Return on Capital Employed (ROCE) | 6.50% | 6.50% | 6.90% | 9.70% | 7.40% | 7.10% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 8.96% | 8.09% | 7.81% | 12.00% | 12.61% | 12.03% |
FCF Yield | 6.20% | 5.60% | -0.73% | 0.26% | 8.60% | 6.34% |
Dividend Yield | 3.02% | 2.54% | 2.45% | 1.89% | 1.44% | 1.29% |
Payout Ratio | 29.81% | 29.81% | 25.00% | 10.50% | 10.66% | 9.28% |
Buyback Yield / Dilution | -0.13% | -0.13% | -0.12% | -0.26% | 0.46% | -0.06% |
Total Shareholder Return | 2.89% | 2.42% | 2.33% | 1.63% | 1.91% | 1.23% |